Evidence map›Paper›PMID 33299651›Full record

ArticleCancer biology & medicine2020

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.

Ying Cheng, Xiaodong Zheng, Xuefu Wang, Yongyan Chen, Haiming Wei, Rui Sun, Zhigang Tian, Haoyu Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Advances in NK cell production.Cellular & molecular immunology · 2022
    Review
  15. Article
  16. Review
  17. Review
  18. A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.International journal of molecular sciences · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ying ChengHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.
Xiaodong ZhengHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.
Xuefu WangHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.
Yongyan ChenHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.
Haiming WeiHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.
Rui SunHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.
Zhigang TianHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.ORCID 0000-0002-5512-6378
Haoyu SunHefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.ORCID 0000-0002-7506-8806

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Natural killer (NK) cells have gained considerable attention due to their potential in treating "cold tumors," and are therefore considered as one of the new strategies for curing cancer, by using worldwide development of their new possibilities and interventions with NK cell-related therapeutic products. Methods: We constructed a trispecific killer engager (TriKE) consisting of anti-CD16, IL-15, and anti-CD19. This TriKE was designed to attract CD19 Results: Treatment with 161519 TriKE in the presence of CD19 Conclusions: The newly generated 161519 TriKE enhanced the proliferation, activation, cytokine secretion, and cytotoxicity of NK cells in the presence of CD19

Indexed as

AnimalsAntigens, CD19Antineoplastic Agents, ImmunologicalCell Line, TumorCytotoxicity, ImmunologicFemaleHumansImmunotherapyKiller Cells, NaturalLymphocyte ActivationMiceMice, Inbred NODNeoplasmsReceptors, IgGXenograft Model Antitumor AssaysAntigens, CD19Antineoplastic Agents, ImmunologicalReceptors, IgGB-cell lymphomaNK cellTrispecific antibodytrispecific killer engager (TriKE)tumor immunotherapy

Identifiers

PMID33299651
PMCPMC7721099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.